Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …
Archives de l’étiquette : Event
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Options XII for the Control of Influenza
Brisbane, Australia – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. Delphine Guyon-Gellin, Chief of Business Development & Chief Operating …
Continuer la lecture « Options XII for the Control of Influenza »
ISIDORe User’s conference
Online – Oral PresentationCharlotte Primard, Non-Clinical Project Manager of Osivax, to provide an update on OVX033 as part of a presentation entitled “Immunogenicity, cross-reactivity and poly-functionality of immune responses induced by OVX033 with and without SQ for SARS-CoV-2”.
Influenza Vaccines for the World 2024
Siena, Italy – Oral PresentationNicola Groth, Chief Medical Officer of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
World Congress Vaccine Washington 2024
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.